Overview

Pulmicort Respules(Budesonide Inhalation Suspension) vs Singulair, Children

Status:
Completed
Trial end date:
2005-02-01
Target enrollment:
Participant gender:
Summary
A one year study comparing the safety and effectiveness of Pulmicort (0.5mg strength given once a day in the evening) with either 4 or 5mg strength SINGULAR (given once a day in the evening) in children with asthma aged 2 to 8. If allocated to SINGULAR treatment, children aged between 2 and 5 will receive 4mg strength SINGULAR and those aged between 6 and 8 will receive 5mg strength SINGULAR.
Phase:
Phase 4
Details
Lead Sponsor:
AstraZeneca
Treatments:
Budesonide
Montelukast